Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07148193

Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

Understanding Long-Term Sarcoma Survivorship: Risk Profiles, Outcomes and Unmet Needs - A Joint Project of Research, Sarcoma Centres and Patient Experts (PROSa+)

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,600 (estimated)
Sponsor
Technische Universität Dresden · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.

Detailed description

Sarcomas are rare cancers that can arise almost anywhere in the body and account for only about one percent of all cancer diagnoses. Both the disease and its treatments often result in late effects, yet knowledge about these long-term consequences remains limited. The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. Particular focus is placed on subgroups with potential long-term risks, including survivors of bone sarcomas, extremity or trunk sarcomas after multimodal treatment, retroperitoneal sarcomas, gastrointestinal stromal tumors (GIST) with or without long-term TKI therapy, and young adult survivors. The mixed-methods research design includes a multicenter observational study with a one-time questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020. Recruitment is built on draws on existing network structures, including the PROSa cohort, the National Center for Tumor Diseases (NCT/UCC) Dresden, the SarcBOP registry at the National Center for Tumor Diseases (NCT) Heidelberg, West German Cancer Center Essen (WTZ), University Hospital Mannheim (UMM), the German Sarcoma Foundation, and cooperating sarcoma centers. Medical data are extracted from patient records. Statistical analyses will include descriptive statistics and regression models to identify impaired quality of life domains and associated factors.

Conditions

Interventions

TypeNameDescription
OTHERNo intervention (observational study)No intervention (observational study)

Timeline

Start date
2025-11-28
Primary completion
2027-09-01
Completion
2027-09-01
First posted
2025-08-29
Last updated
2025-12-08

Locations

5 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT07148193. Inclusion in this directory is not an endorsement.